All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 1: Gastrointestinal
Toggle Parent Pages
Print this page
Inflammatory bowel disease guidance
Irritable bowel syndrome guidance
Management of constipation in adults
Management of constipation in children
Management of dyspepsia and gastro-oesophageal reflux disease
Paediatric reflux disease guidance
Infantile Colic guidance
1.1 Dyspepsia and gastro-oesophageal reflux disease
1.2 Antispasmodics and other drugs altering gut motility
1.3 Antisecretory drugs and mucosal protectants
1.4 Antimotility drugs
1.5 Chronic bowel disorders
1.6 Laxatives
1.7 Local preparations for anal and rectal disorders
1.8 Stoma care
1.9 Drugs affecting intestinal secretions
Contact us about this page
1.9.1 Drugs affecting biliary composition and flow
First Line
Second Line
Specialist
Hospital Only
Ursodeoxycholic acid
- Tablets 150mg, 250mg, 300mg (£18.00 = 60 x 250mg tablets)
- Oral suspension sugar free 250mg in 5ml (£26.98 = 250ml)
Indications and dose
- Dissolution of gallstones
- 8–12mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
- Primary biliary cirrhosis
- 12–16mg/kg daily in 3 divided doses for 3 months, then 12–16mg/kg once daily at bedtime
Obeticholic acid
- Tablets 5mg, 10mg
Notes
- NICE TA443 Obeticholic acid for treating primary biliary cholangitis (April 2017) (NHS England Commissioned)
Odevixibat
- Hard capsules 200 micrograms, 400 micrograms, 600 micrograms, 1,200 micrograms
Notes
- NICE HST17: Odevixibat (Bylvay) is recommended, within its marketing authorisation, as an option for treating progressive familial intrahepatic cholestasis (PFIC) in people 6 months and older (February 2022). It is recommended only if the company provides odevixibat according to the commercial arrangement.
